Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors

NCT00569257 is registered in ClinicalTrials.gov with AEterna Zentaris as lead sponsor.

NCT NCT00569257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00569257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors
Lead sponsor
AEterna Zentaris
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
July 31, 2011
Enrollment
85 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, ovarian cancer